-
公开(公告)号：US20220328185A1
公开(公告)日：2022-10-13
申请号：US17614024
申请日：2020-05-24
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Eran SEGAL , Smadar SHILO , Nitzan ARTZI
Abstract: A method of predicting likelihood for gestational diabetes, comprises: obtaining a plurality of parameters characterizing a female subject, accessing a computer readable medium storing a machine learning procedure trained for predicting likelihoods for gestational diabetes, feeding the procedure with the plurality of parameters, and receiving from the procedure an output indicative of a likelihood that the subject has, or expected to develop, gestational diabetes, wherein the output indicative is related non-linearly to the parameters.
-
公开(公告)号：US20220314221A1
公开(公告)日：2022-10-06
申请号：US17839667
申请日：2022-06-14
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Roy BAR-ZIV , Eyal KARZBRUN , Alexandra TAYAR
Abstract: A microfluidic device is disclosed which comprises: (i) at least one reaction unit having a test chamber connected to at least one microchannel, wherein a surface of at least a portion of said reaction unit is attached to an isolated nucleic acid; and (ii) a flow-through channel having at least one inlet port and at least one outlet port, said flow-through channel and said microchannel being of dimensions to allow reactant diffusion to and from said reaction unit, wherein the diffusion time of said reactant along the microchannel is shorter than the flow time along the microchannel.
-
公开(公告)号：US20220265726A1
公开(公告)日：2022-08-25
申请号：US17737052
申请日：2022-05-05
Applicant: Yeda Research and Development Co. Ltd. , Board of Regents, The University of Texas System
Inventor： Yair REISNER , Aloukick Kumar SINGH
Abstract: A method of treating or preventing a sickle cell disease in a subject in need thereof is disclosed. The method comprising: (a) transplanting immature hematopoietic cells into the subject; and (b) administering to the subject a therapeutically effective amount of an isolated population of non-GVHD inducing anti-third party cells comprising cells having a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance inducing cells and capable of homing to the lymph nodes following transplantation.
-
444.发明申请公开(公告)号：US20220251159A1
公开(公告)日：2022-08-11
申请号：US17549369
申请日：2021-12-13
Applicant: YEDA RESEARCH AND DEVELOPMENT CO., LTD
Inventor： Varda ROTTER , Moshe OREN , Perry TAL , Shay EIZENBERGER , Avi BEN-SHIMON
Abstract: An isolated peptide is provided. The peptide comprises an amino acid sequence arranged in a space and configuration that allow interaction of the peptide with the DNA Binding Domain (DBD) of p53 through at least one residue of the DBD by which pCAP 250 (SEQ ID NO: 1) binds the DBD, wherein the peptide at least partially reactivates a mutant p53 protein, with the proviso that the peptide is not SEQ ID NO: 59-382.
-
公开(公告)号：US20220236356A1
公开(公告)日：2022-07-28
申请号：US17585812
申请日：2022-01-27
Inventor： Noam BEN-ELIEZER , Noam OMER , Meirav GALUN
Abstract: Method for mapping the transverse relaxation times (T2) in a magnetic resonance imaging (MRI) scan defined over a plurality of pixels, where each pixel is associated with a multicomponent T2 (mcT2) signal, comprises: accessing a computer readable medium storing an mcT2 dictionary having a set of synthetic mcT2 signals, and selecting a subset of synthetic mcT2 signals for which correlations between the synthetic mcT2 signals and pixels in the MRI scan are highest among the set. For each of at least a portion of the pixels, a respective mcT2 scan signal is fitted to the subset to provide, a plurality of T2 values for the pixel. A T2 map of the MRI scan is generated based on the T2 values.
-
Patent Agency Ranking
公开(公告)号：US20220236257A1
公开(公告)日：2022-07-28
申请号：US17614563
申请日：2019-06-05
Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.
Inventor： David MARGULIES , Leila MOTIEI , Naama LAHAV
IPC: G01N33/532 , C07K14/705 , G01N33/50 , C12N5/00 , C12N1/00 , C12Q1/02
Abstract: The disclosure presented herein provides artificial receptors and a system comprising recombinant cells decorated with various labels and/or synthetic agents, wherein said labels and/or synthetic agents can be reversibly modified or removed from the cells. Also disclosed herein are methods for decorating and/or modifying the cells and methods for using thereof.
-
公开(公告)号：US20220220559A1
公开(公告)日：2022-07-14
申请号：US17611149
申请日：2020-05-13
Inventor： Eran HORNSTEIN , Iddo MAGEN , Andrea MALASPINA , Pietro FRATTA
IPC: C12Q1/6883 , G01N33/50 , G01N33/68 , A61K31/428 , A61K31/4152 , A61P25/28
Abstract: A method of prognosing a course of disease progression and/or survival time in a subject diagnosed with ALS or FTD is disclosed. The method comprising: (a) detecting a level of miR-181 in a biological sample of the subject; and (b) determining the disease progression and/or survival time based on the level of the miR-181, wherein: (i) when the level of miR-181 is higher than that in a control sample, it is indicative of a rapid disease progression and/or poor survival; or (ii) when the level of miR-181 is about the same or lower than that in the control sample, it is indicative of a slow disease progression and/or good survival. Methods of prognosing a stage of disease in a subject diagnosed with ALS or FTD are also disclosed.
-
公开(公告)号：US20220204928A1
公开(公告)日：2022-06-30
申请号：US17604169
申请日：2020-04-16
Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD. , ICHILOV TECH LTD.
Inventor： Anat AHARON , Anat GLOBERSON LEVIN , Irit AVIVI , Galit HORN , Tova WAKS , Zelig ESHHAR
IPC: C12N5/0783 , C07K16/32 , C07K14/705 , C07K14/725 , A61K45/06 , A61K39/395 , A61K38/17 , A61P35/00 , A61K35/17 , C07K16/28
Abstract: The present invention provides extracellular vesicles (EVs) derived from T-cells expressing chimeric antigen receptors (CAR) specifically activated with an antigen to which the CAR bind specifically, pharmaceutical compositions comprising these vesicles as well as their use in treating cancer. In particular the present invention exemplifies EVs derived from activated T-cells expressing CAR that bind specifically to HER2 cancer antigen, pharmaceutical composition comprising these EVs and their use in treating a cancer overexpressing HER2, such as ovarian cancer and breast cancer.
-
449.发明申请公开(公告)号：US20220202838A1
公开(公告)日：2022-06-30
申请号：US17700063
申请日：2022-03-21
Inventor： Avigdor SCHERZ , Yoram SALOMON , Lilach AGEMY , Rachel HAMRI , Dina PREISE , Kwanghee KIM , Jonathan COLEMAN
IPC: A61K31/675 , A61K31/409 , A61K31/7068 , A61K31/7135 , A61K45/06 , A61P35/00
Abstract: An anti-myeloid-derived suppressor cells agent (“anti-MDSCs agent”) and a bacteriochlorophyll derivative (hereinafter”Bchl-D) for use in combination therapy for cancer. wherein the anti-MDSC agent and the Bchl-D are administered sequentially and the administration of the Bchl-D is followed by photodynamic therapy (PDT) or vascular targeted PDT (VTP).
-
公开(公告)号：US11368670B2
公开(公告)日：2022-06-21
申请号：US16758471
申请日：2018-10-25
Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.
Inventor： Shimon Ullman , Daniel Harari , Liav Assif , Igal Koifman
IPC: H04N13/388 , G02B27/01 , G06T19/00 , G06V20/20
Abstract: A multi-layer viewing system includes a stationary imager and a beam projector to project physical layer markings onto a region of an object. A headset includes an augmented reality display that is sufficiently transparent to enable a user who is wearing the headset to directly view the object through the display, and to display annotation that is superimposed on the object. A processor is configured to receive a selected location relative to the target for display of the annotation, determine an orientation of the augmented reality display by identifying images of markings in acquired images or markings on the object, calculate a display location for displaying the annotation on the augmented reality display such that the annotation is perceivable by the user as displayed at the selected position, and display the annotation at the calculated display location.
-
-
-
-
-
-
-
-
-
Search Results
1003
records
(took 0.04 seconds)
